{"filings":[{"id":91536,"accession_number":"0001140859-26-000018","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Cencora Q2 revenue $78.4B (+3.8%); adj. EPS $4.75 (+7.5%); FY2026 guidance raised","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $8.40 vs $3.68; adjusted diluted EPS $4.75 vs $4.42 (+7.5%).","Revenue $78.4 billion, up 3.8% year-over-year.","FY2026 adjusted diluted EPS guidance raised to $17.65-$17.90 from $17.45-$17.75.","Expects to repurchase ~$1B of shares by end of calendar 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":11.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":164287932000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101685,"accession_number":"0001104659-26-033022","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cencora to buy EyeSouth retina business for $1.1B; expects slight EPS accretion","event_type":"m_and_a","confidence":"high","bullets":["Acquires EyeSouth Partners' retina business for $1.1B; physicians to join Retina Consultants of America.","Deal expected to be slightly accretive to adjusted diluted EPS in first 12 months post-close.","Cencora reaffirms fiscal 2026 financial guidance; transaction not yet reflected in guidance.","Transaction subject to regulatory approvals and customary closing conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101684,"accession_number":"0001104659-26-029039","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Cencora CFO James F. Cleary to retire June 30, 2026; FY2026 guidance reaffirmed","event_type":"leadership","confidence":"high","bullets":["James F. Cleary, EVP and CFO, will retire effective June 30, 2026; advisory role through end of 2026.","Cencora has engaged an executive search firm to identify internal/external successors.","Company reaffirms FY2026 adjusted diluted EPS guidance range of $17.45 to $17.75.","Cleary, 62, joined in 2015 and has served as CFO since November 2018; no disagreement prompted departure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101683,"accession_number":"0001140859-26-000014","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cencora shareholders elect all 11 directors, approve say-on-pay, ratify EY as auditor","event_type":"other","confidence":"high","bullets":["All 11 director nominees elected; for votes ranged from ~163.3M to ~168.5M, with broker non-votes of 9.7M.","Advisory vote on fiscal 2025 named executive officer compensation approved: 156.9M for, 11.4M against, 0.4M abstain.","Ratification of Ernst & Young as independent auditor for FY 2026 approved: 165.7M for, 12.6M against, 0.1M abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101682,"accession_number":"0001104659-26-016785","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cencora merges MWI Animal Health with Covetrus in $3.5B deal; receives cash, preferred and common equity","event_type":"m_and_a","confidence":"high","bullets":["MWI valued at $3.5B enterprise value; Cencora gets $1.25B cash, $800M preferred units, $1.45B common units.","Cencora will hold a non-controlling 34.3% common equity stake in the combined company post-closing.","Transaction subject to regulatory approvals and customary closing conditions; no set closing date.","Cencora reaffirms fiscal 2026 guidance; deal not currently expected to close in FY2026 ending Sep 30, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101681,"accession_number":"0001104659-26-015272","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["1.01","2.03","7.01","8.01","9.01"],"status":"ready","headline":"Cencora closes $3.0B senior notes offering, proceeds to repay OneOncology acquisition debt","event_type":"debt","confidence":"high","bullets":["$500M each of 3.950% notes due 2029, 4.250% notes due 2030, 4.600% notes due 2033, 5.650% notes due 2056; $1.0B of 4.900% notes due 2036.","Net proceeds will repay amounts outstanding under a 364-Day Term Credit Agreement used to fund a portion of the OneOncology acquisition; remainder for general corporate purposes.","Offering closed Feb 13, 2026; joint book-runners: Citigroup, J.P. Morgan, BofA Securities, Wells Fargo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101680,"accession_number":"0001104659-26-013465","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cencora prices $3.0B senior notes offering across five tranches to repay OneOncology acquisition debt","event_type":"debt","confidence":"high","bullets":["$3.0B aggregate of senior notes in five tranches: 2029 (3.950%), 2030 (4.250%), 2033 (4.600%), 2036 (4.900%), 2056 (5.650%).","Net proceeds (~$2.98B) to repay 364-Day Term Loan (used for OneOncology) and for general corporate purposes.","Offering expected to close February 13, 2026; joint book-runners: Citigroup, J.P. Morgan, BofA, Wells Fargo.","Offered under shelf registration filed Nov 26, 2024; underwriting agreement entered Feb 10, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101679,"accession_number":"0001140859-26-000012","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cencora reorganizes segments; explores strategic alternatives for MWI Animal Health, Profarma, U.S. Consulting Services","event_type":"other_material","confidence":"medium","bullets":["New segments: U.S. Healthcare Solutions, International Healthcare Solutions, and Other.","Other includes MWI Animal Health, Profarma, U.S. Consulting Services, and legacy Pharmalex components under strategic review.","Segment reporting change effective Q1 FY2026; historical segment data in 2025 10-K revised but consolidated financials unchanged.","No updates on events after November 25, 2025; first quarter FY2026 10-Q filed February 4, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101678,"accession_number":"0001140859-26-000004","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Cencora Q1 EPS $2.87 GAAP, $4.08 adjusted; acquires OneOncology for $4.6B","event_type":"earnings","confidence":"high","bullets":["Revenue $85.9B, +5.5% YoY; GAAP diluted EPS $2.87 vs $2.50 prior year; adjusted diluted EPS $4.08 vs $3.73, +9.4%.","Completed acquisition of OneOncology on Feb 2 for ~$4.6B in cash funded by new debt; operations consolidated in U.S. Healthcare Solutions.","Adjusted operating income guidance raised to growth of 11.5%-13.5% from prior 8%-10%; adjusted EPS guidance reaffirmed at $17.45-$17.75."],"consensus_eps_estimate":null,"consensus_eps_actual":2.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":85932016000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101677,"accession_number":"0001104659-26-005604","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2026-01-22T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Cencora elects Ellen Cooper, CEO of Lincoln Financial, to its board","event_type":"leadership","confidence":"high","bullets":["Ellen Cooper appointed independent director effective Jan. 20, 2026; board expands from 10 to 11 members.","Cooper is Chairman, President, and CEO of Lincoln Financial; previously at Goldman Sachs, AEGON, and EY.","She will receive standard non-employee director compensation, pro-rated through 2026 annual meeting.","No committee assignment yet; no related-party transactions disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101676,"accession_number":"0001104659-26-004524","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2026-01-16T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Cencora secures $5.5B in financing for OneOncology acquisition; $4.5B bridge replaced","event_type":"debt","confidence":"high","bullets":["Revolving credit facility increased by $1.0B to $5.5B via amendment on Jan 12, 2026.","Entered $1.5B term loan facility ($500M Tranche One, $1.0B Tranche Two) to fund acquisition.","Entered $3.0B 364-day term loan facility to pay consideration and fees for acquisition.","Existing $4.5B bridge financing automatically reduced to zero upon new facilities.","Interest margins range from 75-125 bps over SOFR; leverage covenant max 4.00x with potential increase to 4.50x."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118014,"accession_number":"0001104659-25-120852","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cencora acquires OneOncology majority stake for $3.6B, retires $1.3B debt; total cash ~$5.0B","event_type":"m_and_a","confidence":"high","bullets":["Enterprise value $7.4B; Cencora paying $3.6B for majority equity and retiring $1.3B OneOncology debt.","Acquisition expected to close by end of fiscal Q2 2026, subject to regulatory approvals.","Cencora paused share repurchases; FY2026 adjusted EPS guidance reiterated but likely lower half of $17.45-$17.75.","Long-term guidance raised: adjusted operating income growth 7-10%, adjusted EPS growth 10-14%.","Financing via new debt; $4.5B bridge financing committed; committed to investment grade ratings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118013,"accession_number":"0001140859-25-000128","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Cencora Q4 adj EPS $3.84 (+15%); revenue $83.7B; raises dividend 9%; new segment structure","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP diluted EPS $(1.75) (prior yr $0.02); adjusted EPS $3.84 (+15% YoY); revenue $83.7B (+5.9%).","FY2025 revenue $321.3B (+9.3%); GAAP EPS $7.96; adjusted EPS $16.00 (+16.3%).","Quarterly dividend increased 9%; long-term guidance raised.","New reporting structure Q1 FY26: U.S. Healthcare Solutions, Intl Healthcare Solutions, Other (under strategic review: MWI, Profarma, U.S. Consulting).","U.S. Healthcare Solutions FY2025 op income $3.28B (1.15% margin); Intl Healthcare op income $588M (2.07%)."],"consensus_eps_estimate":null,"consensus_eps_actual":7.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":321332819000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134471,"accession_number":"0001104659-25-088665","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Cencora amends term loan maturity to Oct 2027; money market facility limit raised to $750M","event_type":"debt","confidence":"high","bullets":["Term Loan maturity shortened from Jan 2028 to Oct 1, 2027; interest margin unchanged at 62.5-125 bps over Term SOFR.","Money Market Facility limit raised to $500M (Apr-Nov) and $750M (Dec-Mar), up from prior amounts.","Two lenders (Citibank, Societe Generale) exited the term loan, with loans reassigned to other lenders.","Money market facility remains uncommitted; Société Générale continues as sole lender.","No new borrowing drawn; amendments modify existing credit terms and capacity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134470,"accession_number":"0001104659-25-087080","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cencora reaches $111.3M settlement of derivative suit over opioid oversight","event_type":"litigation","confidence":"high","bullets":["Insurance carriers to pay Cencora $111.3M (less attorney fees) to settle derivative claims over controlled substance diversion controls.","Settlement subject to Delaware Chancery Court approval; defendants deny any wrongdoing or liability.","Derivative complaint alleged breach of fiduciary duty by directors and officers for failing to monitor opioid compliance.","Special Litigation Committee investigated and mediated the resolution; $111.25M mediator proposal accepted June 2025.","Settlement separate from Cencora's prior $6.4B nationwide opioid distributor settlement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134469,"accession_number":"0001104659-25-084068","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Cencora appoints D. Mark Durcan as Chairman effective Oct 1, 2025; Steven H. Collis retires","event_type":"leadership","confidence":"high","bullets":["D. Mark Durcan named Chairman of the Board, effective October 1, 2025, succeeding Steven H. Collis.","Collis retires as Executive Chairman and director at end of fiscal year September 30, 2025; no disagreement cited.","Board size reduces from 11 to 10 directors upon Collis's retirement.","Durcan has been a director since 2015 and Lead Independent Director since March 2023; former CEO of Micron Technology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134468,"accession_number":"0001140859-25-000119","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Cencora Q3 FY2025 revenue $80.7B (+8.7% YoY); adj. EPS $4.00, guidance raised to $15.85-$16.00","event_type":"earnings","confidence":"high","bullets":["Revenue $80.7B (+8.7% YoY); GAAP diluted EPS $3.52 vs $2.42; adj. EPS $4.00, up 19.8%.","Raised FY2025 adj. diluted EPS guidance to $15.85–$16.00 from $15.70–$15.95.","GAAP operating income $0.9B; adjusted operating income $1.1B; net income $687M GAAP / $781M adjusted.","Effective tax rate 23.0% GAAP, 20.7% adjusted; diluted shares 195.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":9.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":237604265000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134467,"accession_number":"0001104659-25-065769","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Cencora increases receivables facility to $1.5B and doubles accordion to $500M","event_type":"debt","confidence":"high","bullets":["Receivables securitization facility raised to $1.5B from $1.45B; accordion feature increased to $500M from $250M.","New uncommitted purchaser Gotham Funding joined the facility; accordion now available in any quarter.","Facility provides additional liquidity backed by AR from ABDC and ASD; Cencora remains performance guarantor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151316,"accession_number":"0001104659-25-057300","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Cencora upsizes revolver to $4.5B, extends maturity to 2030; terminates $1.0B 364-day facility","event_type":"debt","confidence":"high","bullets":["Amended revolving credit facility increased to $4.5 billion aggregate commitments; maturity extended to June 4, 2030.","Interest margins range from 69.5 to 110 bps over Term SOFR (or equivalent) based on credit ratings; facility fee 5.5-15 bps.","Terminated the $1.0 billion 364-day credit agreement originally set to expire January 1, 2026.","Term loan agreement amended to align covenants and pricing with the revolver; leverage ratio covenant remains at 4.0x (4.5x post-material acquisition).","Leverage ratio covenant set at 4.00 to 1.00; may rise to 4.50 to 1.00 after a Material Acquisition over $500 million."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151315,"accession_number":"0001104659-25-053623","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Cencora adds Lori Ryerkerk to board; director Barra resigns amid WBA stake drop","event_type":"leadership","confidence":"high","bullets":["Lori J. Ryerkerk, former Celanese CEO, elected independent director effective June 1, 2025.","Ornella Barra resigned from Cencora board effective May 27, 2025, as Walgreens ownership expected to fall below 5%.","Barra served since 2015; resignation not due to any disagreement with company.","WBA will lose director designation rights when ownership falls below 5%; no replacement director currently planned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151314,"accession_number":"0001104659-25-051974","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Cencora issues €1B in senior notes across 2028 and 2032 maturities","event_type":"debt","confidence":"high","bullets":["Issued €500M of 2.875% Senior Notes due May 22, 2028.","Issued €500M of 3.625% Senior Notes due May 22, 2032.","Notes are unsecured and rank equally with existing unsecured debt.","Interest payable annually starting May 22, 2026; notes redeemable at make-whole or par.","Issued under supplemental indentures with U.S. Bank Trust as trustee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151313,"accession_number":"0001104659-25-050462","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cencora prices €1B dual-tranche senior notes (2.875% due 2028, 3.625% due 2032)","event_type":"debt","confidence":"high","bullets":["€500M 2.875% senior notes due 2028 and €500M 3.625% senior notes due 2032 issued.","Net proceeds estimated at ~€994M after discounts and expenses; intended for general corporate purposes.","Notes are senior unsecured; closing expected on May 22, 2025.","Underwriters include BNP Paribas, Citigroup, J.P. Morgan, Société Générale.","Offering registered under shelf registration statement (Nos. 333-283481) filed Nov 26, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}